BR0111014A - Compostos de praziquantel para o tratamento de doenças causadas por sarcocystis, neospora, toxoplasma e isospora - Google Patents

Compostos de praziquantel para o tratamento de doenças causadas por sarcocystis, neospora, toxoplasma e isospora

Info

Publication number
BR0111014A
BR0111014A BR0111014-4A BR0111014A BR0111014A BR 0111014 A BR0111014 A BR 0111014A BR 0111014 A BR0111014 A BR 0111014A BR 0111014 A BR0111014 A BR 0111014A
Authority
BR
Brazil
Prior art keywords
praziquantel
sarcocystis
diseases caused
treatment
neospora
Prior art date
Application number
BR0111014-4A
Other languages
English (en)
Inventor
Thomas J Kennedy
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0111014A publication Critical patent/BR0111014A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"COMPOSTOS DE PRAZIQUANTEL PARA O TRATAMENTO DE DOENçAS CAUSADAS POR SARCOCYSTIS, NEOSPORA, TOXOPLASMA E ISOSPORA". São divulgadas neste caso composições e processos para tratar terapeuticamente, ou metafilaticamente, mamíferos infectados suscetíveis ou mamíferos infectados que sofrem de doenças neurológicas ou abortigênicas causadas por parasitas tais como Sarcocystis, Neosporose ou Toxoplasmose ou lsosporose que podem ser tratadas com um composto de praziquantel administrando a ele uma composição que contém uma quantidade farmaceuticamente eficaz de praziquantel ou derivado do mesmo, incluindo regimes de tratamento metafilático e de uma única dose alta.
BR0111014-4A 2000-05-23 2001-05-18 Compostos de praziquantel para o tratamento de doenças causadas por sarcocystis, neospora, toxoplasma e isospora BR0111014A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/576,791 US6429211B1 (en) 2000-05-23 2000-05-23 Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora
PCT/US2001/016440 WO2001089497A2 (en) 2000-05-23 2001-05-18 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora

Publications (1)

Publication Number Publication Date
BR0111014A true BR0111014A (pt) 2003-04-08

Family

ID=24306001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111014-4A BR0111014A (pt) 2000-05-23 2001-05-18 Compostos de praziquantel para o tratamento de doenças causadas por sarcocystis, neospora, toxoplasma e isospora

Country Status (19)

Country Link
US (2) US6429211B1 (pt)
EP (1) EP1296686B1 (pt)
JP (1) JP4991076B2 (pt)
KR (1) KR100821112B1 (pt)
CN (1) CN1250222C (pt)
AT (1) ATE310521T1 (pt)
AU (1) AU2001274886A1 (pt)
BR (1) BR0111014A (pt)
CA (1) CA2409926C (pt)
DE (1) DE60115237T2 (pt)
DK (1) DK1296686T3 (pt)
ES (1) ES2252242T3 (pt)
HK (1) HK1059894A1 (pt)
HU (1) HUP0302330A3 (pt)
MX (1) MXPA02011453A (pt)
NZ (1) NZ522687A (pt)
PL (1) PL202041B1 (pt)
WO (1) WO2001089497A2 (pt)
ZA (1) ZA200208770B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061214A1 (en) * 2004-12-10 2006-06-15 Bayer Healthcare Ag Anthelmintic composition
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
US20200138823A1 (en) * 2018-11-02 2020-05-07 Adamis Pharmaceuticals Corporation Drug compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2362539C2 (de) 1973-12-17 1986-05-07 Merck Patent Gmbh, 6100 Darmstadt 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US4447414A (en) 1982-12-21 1984-05-08 Cutter Laboratories, Inc. Carnivore anthelmintics
DE3634755A1 (de) * 1986-10-11 1988-04-14 Bayer Ag Dermale behandlung von wurmerkrankungen der katze mit praziquantel
DE3805660A1 (de) 1988-02-24 1989-09-07 Bayer Ag Substituierte 1,2,4-triazindione, verfahren zu ihrer herstellung und ihre verwendung
DE3826058A1 (de) 1988-07-30 1990-02-08 Bayer Ag Mittel gegen fischparasiten
US4933341A (en) 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US5196562A (en) 1988-10-08 1993-03-23 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
EP0377903A3 (de) 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
CN1044905A (zh) 1989-02-16 1990-08-29 赫彻斯特股份公司 鱼和昆虫寄生虫对抗剂
DE4030042A1 (de) 1990-05-17 1991-11-21 Bayer Ag Verwendung von substituierten 1,2,4-triazindionen
DE4120138A1 (de) 1991-06-19 1992-12-24 Bayer Ag Substituierte hexahydro-1,2,4-triazindione, verfahren zu ihrer herstellung, zwischenprodukte dafuer und ihre verwendung
AUPM969994A0 (en) 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
US5663155A (en) 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
JPH0987196A (ja) * 1995-09-25 1997-03-31 Masatoshi Nakano 寄生虫駆除・駆虫剤
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
AU5529600A (en) * 1999-06-18 2001-01-09 Bayer Aktiengesellschaft Anthelmintic compositions

Also Published As

Publication number Publication date
NZ522687A (en) 2004-07-30
EP1296686B1 (en) 2005-11-23
PL202041B1 (pl) 2009-05-29
DE60115237T2 (de) 2006-06-29
DK1296686T3 (da) 2006-04-03
CN1452489A (zh) 2003-10-29
PL360503A1 (en) 2004-09-06
HK1059894A1 (en) 2004-07-23
DE60115237D1 (de) 2005-12-29
ES2252242T3 (es) 2006-05-16
US20020143018A1 (en) 2002-10-03
MXPA02011453A (es) 2003-05-23
ATE310521T1 (de) 2005-12-15
WO2001089497A3 (en) 2002-11-28
HUP0302330A3 (en) 2012-02-28
KR20020097257A (ko) 2002-12-31
CA2409926A1 (en) 2001-11-29
US6429211B1 (en) 2002-08-06
AU2001274886A1 (en) 2001-12-03
ZA200208770B (en) 2003-10-30
CA2409926C (en) 2009-11-03
JP4991076B2 (ja) 2012-08-01
HUP0302330A2 (hu) 2003-11-28
WO2001089497A2 (en) 2001-11-29
JP2003534275A (ja) 2003-11-18
EP1296686A2 (en) 2003-04-02
CN1250222C (zh) 2006-04-12
KR100821112B1 (ko) 2008-04-11

Similar Documents

Publication Publication Date Title
BR0310092A (pt) Combinação de compostos orgânicos
UY35542A (es) Métodos y composiciones para tratar el virus de la hepatitis c
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ES2155601T3 (es) Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.
BRPI0410235A (pt) inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
EA200001085A1 (ru) 5-аминоиндено [1, 2-с]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
GT199700009AA (es) Terapia combinada para la osteoporosis
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
AR003119A1 (es) Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres
PT1140102E (pt) Compostos de triazinona para tratar doencas causadas por sarcosystis, neospora etoxoplasma
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0111014A (pt) Compostos de praziquantel para o tratamento de doenças causadas por sarcocystis, neospora, toxoplasma e isospora
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
BR9916391A (pt) Compostos de triazineona para o tratamento de doenças causadas por sarcosiste, neopora e toxoplasma
BR9916417A (pt) Compostos triazinaona para tratamento de doenças devidas à sarcosystis, neospora e toxoplasma
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
BR0214564A (pt) Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
ATE526992T1 (de) Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/47; A61P 33/10

Ipc: A61K 31/00 (2011.01), A61P 33/10 (2011.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.